OverviewSuggest Edit

Omeros Corporation is a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics, orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The Company markets OMIDRIA for use during cataract surgery or intraocular lens replacement. Its clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome, and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy and other renal diseases.

TypePublic
Founded1994
HQSeattle, US
Websiteomeros.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Feb 2019)173
Revenue (FY, 2018)$29.9 M(-53%)
Share Price (Nov 2019)$13.7

Key People/Management at Omeros

Gregory A. Demopulos

Gregory A. Demopulos

Chairman and Chief Executive Officer
Christopher S. Bral

Christopher S. Bral

Vice President, Nonclinical Development
Timothy M. Duffy

Timothy M. Duffy

Vice President, Business Development
Edeki M.D.

Edeki M.D.

Vice President, Clinical Development
George A. Gaitanaris

George A. Gaitanaris

Chief Scientific Officer
Michael A. Jacobsen

Michael A. Jacobsen

Chief Accounting Officer
Show more

Omeros Office Locations

Omeros has an office in Seattle
Seattle, US (HQ)
Waterfront Research Center, 201 Elliott Ave W
Show all (1)

Omeros Financials and Metrics

Omeros Revenue

Omeros's revenue was reported to be $29.87 m in FY, 2018
USD

Revenue (FY, 2018)

29.9m

Gross profit (FY, 2018)

29.4m

Gross profit margin (FY, 2018), %

98.3%

Net income (FY, 2018)

(126.8m)

EBIT (FY, 2018)

(112.2m)

Market capitalization (12-Nov-2019)

675.2m

Closing stock price (12-Nov-2019)

13.7

Cash (31-Dec-2018)

5.9m
Omeros's current market capitalization is $675.2 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

1.6m539.0k13.3m41.6m64.8m29.9m

Revenue growth, %

(66%)2406%208%

Cost of goods sold

1.0m1.4m1.1m512.0k

Gross profit

12.2m40.2m63.7m29.4m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

196.0k100.0k45.0k214.0k388.0k3.2m3.3m7.4m10.0m11.3m12.3m17.2m21.7m3.2m

Cost of goods sold

11.0k365.0k248.0k327.0k327.0k378.0k271.0k157.0k184.0k203.0k319.0k

Gross profit

377.0k2.8m3.0m7.1m9.7m10.9m12.0m17.0m21.5m2.9m

Gross profit Margin, %

97%89%92%96%97%97%98%99%99%90%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

1.4m354.0k1.4m2.2m3.4m5.9m

Accounts Receivable

379.0k392.0k6.5m14.6m

Prepaid Expenses

251.0k1.2m1.9m1.8m

Inventories

337.0k568.0k472.0k1.1m443.0k88.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

1.2m567.0k1.5m750.0k1.4m2.6m601.0k978.0k4.6m10.3m1.3m3.4m1.0m1.2m2.9m

Accounts Receivable

538.0k3.1m2.5m6.6m8.8m10.5m13.5m19.1m24.6m

Prepaid Expenses

1.8m1.4m1.4m2.5m2.3m1.4m3.3m3.4m5.7m

Inventories

566.0k633.0k445.0k2.0m1.8m1.4m960.0k905.0k822.0k247.0k235.0k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(39.8m)(73.7m)(75.1m)(66.7m)(53.5m)(126.8m)

Depreciation and Amortization

302.0k326.0k209.0k300.0k551.0k962.0k

Inventories

(568.0k)96.0k(656.0k)685.0k355.0k

Accounts Payable

(1.2m)4.2m(319.0k)10.5m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(38.0m)(16.6m)(34.6m)(53.0m)(18.7m)(35.3m)(55.3m)(20.5m)(33.2m)(47.1m)(15.1m)(29.4m)(36.9m)(30.1m)(63.7m)

Depreciation and Amortization

222.0k82.0k164.0k246.0k55.0k107.0k161.0k53.0k122.0k211.0k115.0k234.0k378.0k1.1m429.0k

Inventories

(159.0k)(1.5m)(1.3m)(924.0k)168.0k223.0k306.0k196.0k208.0k

Accounts Payable

453.0k4.0m4.3m3.9m(1.9m)(1.2m)721.0k1.3m(268.0k)(303.0k)771.0k8.4m8.1m
USDY, 2018

Revenue/Employee

172.6k
Show all financial metrics

Omeros Operating Metrics

FY, 2014FY, 2015FY, 2016

Patents (Foreign)

41 55 63

Patents Pending (Foreign)

66 72 73

Patents (US)

271 310 492

Patents Pending (US)

300 327 313
Show all operating metrics

Omeros Online and Social Media Presence

Embed Graph

Omeros News and Updates

Omeros Announces Proposed $210 Million Offering of Convertible Senior Notes Due 2023

SEATTLE, Nov. 8, 2018 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER) ("Omeros") today announced its intention to offer, subject to market and other conditions, $210 million aggregate principal amount of its Convertible Senior Notes due 2023 (the "Notes") in a private offering (the...
Show more

Omeros Frequently Asked Questions

  • When was Omeros founded?

    Omeros was founded in 1994.

  • Who are Omeros key executives?

    Omeros's key executives are Gregory A. Demopulos, Christopher S. Bral and Timothy M. Duffy.

  • How many employees does Omeros have?

    Omeros has 173 employees.

  • What is Omeros revenue?

    Latest Omeros annual revenue is $29.9 m.

  • What is Omeros revenue per employee?

    Latest Omeros revenue per employee is $172.6 k.

  • Who are Omeros competitors?

    Competitors of Omeros include BeyondSpring, Catalyst Pharmaceuticals and Akorn.

  • Where is Omeros headquarters?

    Omeros headquarters is located at Waterfront Research Center, 201 Elliott Ave W, Seattle.

  • Where are Omeros offices?

    Omeros has an office in Seattle.

  • How many offices does Omeros have?

    Omeros has 1 office.